Panavance Therapeutics

Panavance Therapeutics Unveils Promising Data on Misetionamide’s Dual Cancer Targeting Mechanism

BERWYN, PA — Panavance Therapeutics Inc. has announced groundbreaking findings this week, demonstrating the potential of their investigational drug, misetionamide (GP-2250), to tackle various forms of cancer by directly inhibiting …

Panavance Therapeutics Unveils Promising Data on Misetionamide’s Dual Cancer Targeting Mechanism Read More

DNA

Revolutionary Gene Therapy Approved: Kebilidi Offers New Hope for Rare Genetic Disorder

WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has announced a groundbreaking approval of Kebilidi (eladocagene exuparvovec-tneq), marking the first gene therapy sanctioned for the treatment of aromatic L-amino …

Revolutionary Gene Therapy Approved: Kebilidi Offers New Hope for Rare Genetic Disorder Read More